BBNX Earnings

BBNX reported its earnings on 2026-02-17, showcasing a revenue of against an estimate of 27.99M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.42 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following BBNX's earnings announcement on 2026-02-17, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, BBNX's stock price tends to shift by an average of -8.07% in the 10 days leading up to earnings and +4.76% in the 10 days following, providing insight into potential market.

For , analysts estimate BBNX’s annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 0.03% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between BBNX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 0.03% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BBNX's stock price typically moves by -8.07% in the 10 days before its earnings and +4.76% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

Beta Bionics has raised its full-year 2025 guidance for both net sales and gross margins, indicating strong financial performance. The Q&A section reveals consistent revenue momentum, expansion into new territories, and improvements in product features. While there are concerns regarding management's lack of clarity on some issues, the overall sentiment is positive due to the raised guidance and strong growth drivers. Despite increased operating expenses, the company's cash position remains robust, supporting further growth initiatives.